Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCT-100 in relapsed or refractory pediatric and young adult cancers
NL-OMON49172Phase 2Active, not recruiting
- Sponsor
- Cancer Research UK
- Start
- Jun 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arginase-1 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma and 2 more, sponsored by Cancer Research UK. Primary endpoints: Recommended phase II dose, Dose-limiting toxicity and 2 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
arginase-1
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)neuroblastomaBone and soft tissue sarcomaglioma
Beyond the preview
Go deeper on NL-OMON49172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49172.